

REMARKS

In the Advisory Action detailed in Paper No. 20070828, it is stated that the optional therapeutic agents are not exclusive of acid salts of analgesics. As a result, the rejections were maintained. By way of this amendment, dependent claims 19, 20 and 24 have been amended and new claims 31-34 added. As a result, claims 19, 20 and 24-34 are the claims pending in the application. Claims 19, 20, 24, 26, 27 and 30 currently stand rejected under 35 U.S.C. §102(b) as being anticipated by Mantelle (U.S. Patent No. 5,446,070). Additionally, claims 25, 28 and 29 stand rejected under 35 U.S.C. §103(a) as being unpatentable over Mantelle in view of Swinehart (U.S. Patent No. 5,961,997). Support for the amendments to claims 19, 20 and 24 as well as new claims 31-34 is found in the specification at page 6, lines 19-20; page 19, lines 10-18 and page 24, lines 4-12. As such, it is submitted that no new matter has been added to the application by way of these amendments.

In light of the above amendments, Applicant submits that independent claims 19, 20 and 24 as well as new claims 31-34 are not anticipated by Mantelle. The remarks made of record in the response filed July 31, 2007 found on pages 2-5 are hereby incorporated by reference as being relevant to the allowability of the pending claims. Reconsideration and withdrawal of the outstanding rejections is therefore solicited.

Dated: October 16, 2007

Respectfully submitted,

By: /Avery N. Goldstein, Ph.D./

Avery N. Goldstein, Ph.D.

Registration No.: 39,204

GIFFORD, KRASS, SPRINKLE, ANDERSON
& CITKOWSKI, P.C.

2701 Troy Center Drive, Suite 330

Post Office Box 7021

Troy, Michigan 48007-7021

(248) 647-6000

Attorney for Applicant